OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	827
Characterization of gH/gL/pUL128-131 pentameric complex, gH/gL/gO trimeric complex, gB and gM/gN glycoproteins in a human cytomegalovirus using automated capillary western blots	217
Editorial Board/Aims and Scope	198
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	192
Editorial Board/Aims and Scope	172
Managing multiplicity in clinical vaccine studies – A case study using a gatekeeping testing strategy	147
Editorial Board/Aims and Scope	138
The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs	130
Tackling the burden of mumps in the military: A report of the Defense Health Board	126
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	125
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	123
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	113
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	110
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	105
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	98
Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling	97
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	94
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	93
Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study	89
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	88
Characteristics of reported mumps cases in the United States: 2018–2023	88
“Every interaction you have …should be an opportunity to discuss and offer influenza vaccination”. Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families li	87
Editorial Board/Aims and Scope	85
Editorial Board/Aims and Scope	81
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	81

BCG for the prevention and treatment of allergic asthma	80
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants	80
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	78
Corrigendum to ‘Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice’ [Vaccine 39 (2021) 6213–6220]	77
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	76
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	75
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	75
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	73
Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate	71
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season	71
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	70
Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador	70
Effectiveness of the varicella vaccine in the real world, a matched case-control study	70
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines	69
A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein	69
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	68
RSV neutralization assays – Use in immune response assessment	68
Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria	68
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	68
The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies	67
COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort	65
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study	65
Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan	65
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP)	63
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2	63
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink	63
Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children	63
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	63
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States	61
Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate	59
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England	58
Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents	57